Creative Planning
OREX

Creative Planning’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Creative Planning’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-6,700
Closed -$2K – 5124
2016
Q3 		$2K Buy
+6,700
New +$25.3K ﹤0.01% 4331
2016
Q1 		– Sell
-810
Closed -$2K – 4843
2015
Q4 		$2K Buy
+810
New +$19.3K ﹤0.01% 4154
2015
Q1 		– Sell
-400
Closed -$2K – 4691
2014
Q4 		$2K Buy
+400
New +$20.1K ﹤0.01% 3926

Other funds holding OREX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
OWIM
Old West Investment Management Los Angeles, California $923M AUM 112.31% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Creative Planning's OREX Position: Q3 2017 in Review

Creative Planning sold out of Orexigen Therapeutics, Inc. (OREX) in Q3 2017, closing a stake of 126 shares.

Creative Planning first reported a position in OREX in Q2 2013 and held it in 17 quarters. The position peaked at $251K in Q4 2015. 42 funds tracked by Wall St. Rank hold OREX as of Q3 2017.

  • Creative Planning reported no remaining Orexigen Therapeutics, Inc. position as of Q3 2017 after selling out during the quarter.
  • Creative Planning sold 126 Orexigen Therapeutics, Inc. shares in Q3 2017.
  • Creative Planning first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and held it in 17 quarters.
  • Creative Planning's Orexigen Therapeutics, Inc. position peaked at $251K in Q4 2015.
  • 42 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q3 2017.

Based on Creative Planning's 13F filing for Q3 2017, filed 17 Oct 2017.